Stereotaxis Q1 2024 GAAP EPS $(0.06), Inline, Sales $6.880M Miss $7.000M Estimate

5/13/24 4:17:49 PM ET

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Health Care

Get the next $STXS alert in real time by email

Stereotaxis (AMEX:STXS) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 14.29 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $6.880 million which missed the analyst consensus estimate of $7.000 million by 1.71 percent. This is a 5.07 percent increase over sales of $6.548 million the same period last year.

Get the next $STXS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$STXS

Date	Price Target	Rating	Analyst
1/10/2024	$5.00	Buy	ROTH MKM
7/12/2022	$6.00	Buy	Aegis Capital
6/23/2022	$6.00	Buy	B. Riley Securities
1/5/2022	$11.00	Buy	Craig-Hallum
1/5/2022	$13.00	Buy	Loop Capital

More analyst ratings

$STXS
Press Releases

Fastest customizable press release news feed in the world

Hospital Da Luz is the First in Portugal to Adopt Genesis Robotic System
ST. LOUIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at the Hospital da Luz in Lisbon, Portugal have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System. "We are excited to be at the forefront of technology and patient care by introducing the new Genesis System at Hospital da Luz," said Prof. Pedro Adragão, Cardiac Electrophysiologist at Hospital da Luz. "Robotics allows us to treat patients with effective individualized therapy and the highest focus on safety. We are pleased to offer thi
11/20/24 8:18:00 AM ET
$STXS
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Stereotaxis Reports 2024 Third Quarter Financial Results
ST. LOUIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2024. "The past quarter was marked by solid commercial execution, continued broad-based technological progress, successful operational integration of APT, and maintained financial discipline," said David Fischel, Chairman and CEO. "We are making broad, methodical progress in establishing the healthy foundations for a preeminent robotic surgery company." "Revenue growth in the third quarter was driven by continued demand for Genesis with par
11/11/24 4:02:00 PM ET
$STXS
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
University of Kansas Medical Center Enhances Robotic Heart Care Program with Genesis Robotic Technology
ST. LOUIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at the University of Kansas Health System have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System from Stereotaxis. The health system is renowned for diagnosing and treating complex heart conditions. The Genesis System is the latest advancement in Robotic Magnetic Navigation technology. Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to cardiac ablation, a common minimally invasive procedure to treat
11/6/24 8:25:00 AM ET
$STXS
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care

$STXS
Financials

Live finance-specific insights

Stereotaxis Reports 2024 Third Quarter Financial Results
ST. LOUIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2024. "The past quarter was marked by solid commercial execution, continued broad-based technological progress, successful operational integration of APT, and maintained financial discipline," said David Fischel, Chairman and CEO. "We are making broad, methodical progress in establishing the healthy foundations for a preeminent robotic surgery company." "Revenue growth in the third quarter was driven by continued demand for Genesis with par
11/11/24 4:02:00 PM ET
$STXS
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Stereotaxis to Report Third Quarter 2024 Financial Results on November 11, 2024
ST. LOUIS, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 third quarter on Monday, November 11, 2024 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company's results and corporate developments. What: Stereotaxis third quarter 2024 financial results conference call When: Monday, November 11, 2024, at 4:30 p.m. ET (1:30 p.m. PT) Dial In Number: To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963
10/23/24 9:00:00 AM ET
$STXS
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Stereotaxis Reports 2024 Second Quarter Financial Results
ST. LOUIS, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2024. "We made significant progress over the last quarter on strategic innovation efforts that are establishing a solid foundation upon which to build a substantial and successful company," said David Fischel, Chairman and CEO. "Key milestones achieved include successfully obtaining CE mark in Europe and submitting a 510(k) application in the US for GenesisX, substantial progress with regulatory reviews of MAGiC in Europe and the US, and closing the acq
8/12/24 4:05:00 PM ET
$STXS
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care

Stereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation
ST. LOUIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will participate in the Society for Cardiac Robotic Navigation's Annual Meeting taking place October 28-29 in Lisbon, Portugal. The global physician-led Society for Cardiac Robotic Navigation (SCRN) is dedicated to establishing a community and platform for users of robotic technologies in cardiology. The annual SCRN conference provides a venue for physicians and healthcare professionals to share best practices, discuss new clinical literature, and evaluate the latest innovations in technology. The
10/21/24 8:41:13 AM ET
$STXS
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Stereotaxis Strengthens Board of Directors with Appointment of Nachum Shamir
ST. LOUIS, July 18, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced the appointment of Nachum "Homi" Shamir to its Board of Directors. Mr. Shamir most recently served as Chairman and Chief Executive Officer of Luminex Corporation from 2014 through its sale to DiaSorin S.p.A. for $1.8 Billion in 2021. Prior to Luminex, Mr. Shamir served as President and Chief Executive Officer of Given Imaging from 2006 through its sale to Covidien for $1 Billion in 2014. He currently serves as Chairman of Mediwound, a publicly-traded leader in enzymatic therapeutics for burn and wound-care, and SSI Diagnosti
7/18/24 4:13:00 PM ET
$STXS
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Stereotaxis Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D.
ST. LOUIS, July 26, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the appointment of Myriam J. Curet, M.D., to its Board of Directors. Dr. Curet currently serves as Executive Vice President and Chief Medical Officer for Intuitive Surgical, the global leader and pioneer of robotic surgery. Dr. Curet joined Intuitive Surgical in 2005 and has since led the development of clinical evidence, physician education, and reimbursement and regulatory activities that have been instrumental to Intuitive Surgical's growth across multiple clinical specialties. For more than 20 years, Dr. Cu
7/26/21 9:00:00 AM ET
$STXS
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care

Stereotaxis Q1 2024 GAAP EPS $(0.06), Inline, Sales $6.880M Miss $7.000M Estimate

Chat with this insight

Recent Analyst Ratings for $STXS

$STXS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Stereotaxis Inc.

Director Isaac Paul J bought $15,350 worth of shares (8,095 units at $1.90) (SEC Form 4)

SEC Form 3 filed by new insider Shamir Nachum

$STXS Press Releases

Fastest customizable press release news feed in the world

Hospital Da Luz is the First in Portugal to Adopt Genesis Robotic System

Stereotaxis Reports 2024 Third Quarter Financial Results

University of Kansas Medical Center Enhances Robotic Heart Care Program with Genesis Robotic Technology

$STXS Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Isaac Paul J bought $15,350 worth of shares (8,095 units at $1.90) (SEC Form 4)

Director Isaac Paul J bought $13,017 worth of shares (7,000 units at $1.86) (SEC Form 4)

Isaac Paul J bought $1,958 worth of shares (1,000 units at $1.96) (SEC Form 4)

$STXS Market Insights

Live Market Insights

Hyliion Holdings And 3 Other Penny Stocks Insiders Are Buying

Stereotaxis Announces Penn Presbyterian Medical Center First Treats First Heart Rhythm Patients Using Genesis Robotic Magnetic Navigation System.

Stereotaxis Receives CE Mark Recertification Under EU's Medical Device Regulation Regulatory Framework

$STXS SEC Filings

SEC Form 10-Q filed by Stereotaxis Inc.

Stereotaxis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

SEC Form EFFECT filed by Stereotaxis Inc.

$STXS Financials

Live finance-specific insights

Stereotaxis Reports 2024 Third Quarter Financial Results

Stereotaxis to Report Third Quarter 2024 Financial Results on November 11, 2024

Stereotaxis Reports 2024 Second Quarter Financial Results

$STXS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

ROTH MKM initiated coverage on Stereotaxis with a new price target

Aegis Capital initiated coverage on Stereotaxis with a new price target

B. Riley Securities initiated coverage on Stereotaxis with a new price target

$STXS Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Stereotaxis Inc. (Amendment)

SEC Form SC 13G/A filed by Stereotaxis Inc. (Amendment)

SEC Form SC 13G/A filed by Stereotaxis Inc. (Amendment)

$STXS Leadership Updates

Live Leadership Updates

Stereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation

Stereotaxis Strengthens Board of Directors with Appointment of Nachum Shamir

Stereotaxis Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D.

Recent Analyst Ratings for
$STXS

$STXS
Insider Trading

$STXS
Press Releases

$STXS
Insider Purchases

$STXS
Market Insights

$STXS
SEC Filings

$STXS
Financials

$STXS
Analyst Ratings

$STXS
Large Ownership Changes

$STXS
Leadership Updates